Molecular hybridization strategies for developing antidiabetic agents with optimized therapeutic efficacy

Abstract

Diabetes mellitus is a complex, heterogeneous metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion and action, a major global metabolic disorder, with type 2 diabetes (T2DM) constituting the predominant disease burden. Existing antidiabetic agents, such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and α-glucosidase inhibitors, provide important clinical benefits but are limited by single-target mechanisms, diminishing long-term efficacy, adverse effects including hypoglycemia, weight gain, gastrointestinal intolerance and cardiovascular risk, and the need for complex combination therapy. These drawbacks highlight the need for multi-functional chemotypes capable of addressing the multifactorial pathophysiology of T2DM within a single molecular framework. Molecular hybridization, a modern synthetic drug discovery approach that integrates multiple pharmacophoric units into a single chemical entity, has been reported to overcome these limitations by creating multifunctional agents capable of simultaneously modulating diverse pathogenic pathways. This review surveys more than 75 reported antidiabetic hybrids based on chalcone–coumarin, thiazolidinedione–fibrate, pyrazole–triazole, benzimidazole, benzothiazole and related structures, summarizing their in vitro enzyme inhibition profiles, in silico studies and in vivo antidiabetic activities. Many of these hybrids exhibit dual or multitarget pharmacology, with in vitro enzyme inhibition assays, cellular assays, and animal studies confirming enhanced in vitro potency, supported by computational methods. Overall findings indicate more balanced physicochemical and pharmacokinetic profiles in in vitro and preclinical studies relative to parent compounds and existing drugs, though validation in human studies is required. Collectively, the available data support molecular hybridization as a versatile platform for developing next-generation antidiabetic agents that integrate enhanced in vitro potency, optimized physicochemical and pharmacokinetic properties, reduced polypharmacy and drug-drug interaction burden, and lower side-effect risk in animal studies, though clinical studies are required, before any implications for long-term patient adherence or therapeutic superiority over conventional single-target therapies can be established.